Author information:
(1)Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, 
Division of Cardiology, Toronto General Hospital, University of Toronto, 
Toronto, Ontario, Canada. Electronic address: dinesh.thavendiranathan@uhn.ca.
(2)Cardio-Oncology Program, Division of Cardiology, Department of Medicine, 
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, 
USA.
(3)Cardiovascular Imaging Research Center, Division of Cardiology and Department 
of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
(4)Cardiovascular Imaging Research Center, Division of Cardiology and Department 
of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Heart 
and Vascular Center, Semmelweis University, Budapest, Hungary.
(5)Cardiology Division, NewYork-Presbyterian Hospital, Weill Cornell Medical 
Center, New York, New York, USA.
(6)Department of Cardiology or Diagnostic Radiology, Jewish General Hospital, 
McGill University, Montreal, Quebec, Canada.
(7)Cardiovascular Imaging Research Center, Division of Cardiology and Department 
of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA; 
Cardio-Oncology Program, Division of Cardiology, Department of Medicine, 
Massachusetts General Hospital, Boston, Massachusetts, USA.
(8)Cardio-Oncology Program, Division of Cardiology, Department of Medicine, 
Brigham and Women's Hospital, Boston, Massachusetts, USA.
(9)University Mediterranean Center of Cardio-Oncology, Nord Hospital, 
Aix-Marseille University, Marseille, France; Groupe Méditerranéen de 
Cardio-Oncologie, Marseille, France; Center for CardioVascular and Nutrition 
Research, INRA 1260, INSERM 1263, Aix-Marseille University, Marseille, France.
(10)Department of Dermatology, University Hospital Erlangen, 
Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; Department 
of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of 
Munich, Munich, Germany.
(11)Cardio-Oncology Program, MedStar Heart and Vascular Institute, Georgetown 
University, Washington, DC, USA.
(12)Division of Oncology and Hematology, Department of Medicine, Massachusetts 
General Hospital, Boston, Massachusetts, USA.
(13)Cardiology Division, Memorial Sloan Kettering Cancer Center, Weill Cornell 
Medical College, New York, New York, USA.
(14)Department of Dermatology, University Hospital Erlangen, 
Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
(15)Cardiology Division, NewYork-Presbyterian Hospital, Weill Cornell Medical 
Center, New York, New York, USA; Cardiology Division, Memorial Sloan Kettering 
Cancer Center, Weill Cornell Medical College, New York, New York, USA.
(16)Division of Oncology and Hematology, Department of Medicine, Lehigh Valley 
Hospital, Allentown, Pennsylvania, USA.
(17)Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.
(18)Hospital General Universitario Gregorio Marañón, CIBERCV, Instituto de Salud 
Carlos III, Universidad Complutense de Madrid, Madrid, Spain.
(19)Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
(20)Cardio-Oncology Program, Division of Cardiovascular Medicine, Lahey Hospital 
and Medical Center, Burlington, Massachusetts, USA.
(21)Cardio-Oncology Program, Department of Cardiology, Clínica Universidad de 
Navarra, Pamplona and Madrid, Spain.
(22)Cardiovascular Imaging Program, Cardiovascular Division and Department of 
Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
(23)Cardiology Division, State University of Campinas, Campinas, Brazil.
(24)Cardiovascular Research Centre and Cardiovascular Magnetic Resonance Unit, 
Royal Brompton Hospital, National Heart and Lung Institute, Imperial College 
London, London, United Kingdom.
(25)Department of Medical Imaging, Toronto General Hospital, University Health 
Network, University of Toronto, Toronto, Ontario, Canada.
(26)Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, 
Division of Cardiology, Toronto General Hospital, University of Toronto, 
Toronto, Ontario, Canada.
(27)Cardio-Oncology Program, Division of Cardiology, Hôpitaux Universitaires Est 
Parisien, Paris, France.
(28)UCLA Cardio-Oncology Program, Division of Cardiology, Department of 
Medicine, University of California, Los Angeles, Los Angeles, California, USA.
(29)Cardio-Oncology Program, Royal Brompton Hospital, Imperial College London, 
London, United Kingdom.
(30)Cardio-Oncology Center of Excellence, Division of Cardiology, Department of 
Medicine, Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia, Pennsylvania, USA.
(31)Cardiovascular Imaging Research Center, Division of Cardiology and 
Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, 
USA; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, 
Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: 
tneilan@mgh.harvard.edu.